t
Iconic Labs PLC received a Conversion Notice dated 2 February 2023 from the European High Growth Opportunities Securitization Fund (EHGOSF). This converted 100 Convertible Notes, with an aggregate principal amount of £100,000, into 1,234,567,901 new ordinary shares at a conversion price of £0.000081. Application is being made for these shares to be admitted to trading on the London Stock Exchange around 9 February 2023, after which the total issued ordinary share capital will be 40,898,270,045 Ordinary Shares.
| Date | 6 Feb 2023 |
| Time | 07:18:19 |
| Category | Corporate updates |
| ID | 0040P |
Iconic Labs PLC
("Iconic" or the "Company")
Conversion of Notes
Iconic Labs PLC (LSE:ICON), a multi-divisional new media and technology business, announces that it has received a valid Conversion Notice from the European High Growth Opportunities Securitization Fund ("EHGOSF").
Conversion of Loan Notes
The Conversion Notice was dated 2 February 2023 and provides for 100 Convertible Notes to be converted into 1,234,567,901 ordinary shares of £0.00001 ("Ordinary Shares") in the Company at a conversion price of £0.000081 at the aggregate principal amount of £100,000.
Application is being made for the 1,234,567,901 new Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange which is expected to be on or around 9 February 2023. These shares rank pari passu with the existing Ordinary Shares of the Company.
Following the issue of these shares, the Company's issued ordinary share capital shall consist of 40,898,270,045 Ordinary Shares. The figure of 40,898,270,045 represents the total voting rights in the Company and should be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance & Transparency Rules.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
For any further information or enquiries please contact: